Antibiotics are the mainstay of treatment for bacterial infections in patients of all ages. Athletes who maximally train are at risk for illness and various infections. Routinely used antibiotics have been linked to tendon injuries, cardiac arrhythmias, diarrhea, photosensitivity, cartilage issues, and decreased performance.
Evidence Acquisition:
Relevant articles published from 1989 to 2012 obtained through searching MEDLINE and OVID. Also, the Food and Drug Administration website was utilized.
Study Design:
Clinical review.
Level of Evidence:
Level 3.
Results:
The team physician should consider alternative medications in place of the “drug of choice” when adverse drug effects are a concern for an athlete’s health or performance. If alternative medications cannot be selected, secondary preventative measures, including sunscreen or probiotics, may be needed.
Conclusion:
Physicians choose medications based on a variety of factors to help ensure infection resolution while limiting potential side effects. Extra precautions are indicated when treating athletes with certain antibiotics.
AlarantaAAlarentaHHeleniusI. Use of prescription drugs in athletes. Sports Med. 2008;38:449-463.
2.
AlarantaAAlarantaHHeliövaaraMAiraksinenMHeleniusI. Ample use of physician-prescribed medications in Finnish elite athletes. Int J Sports Med. 2006;27:919-925.
3.
AyangcoLSheridanPJ. Minocycline-induced staining of torus palatinus and alveolar bone. J Periodontol. 2003;75:669-671.
4.
BakerCS. Photosensitivity. Med J Aust. 1996;165:96-101.
5.
BalkSJ; Council on Environmental Health; Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics. 2011;127:e791-817.
6.
BergerRSMandelEBHayesTJGrimwoodRR. Minocycline staining of the oral cavity. J Am Acad Dermatol. 1989;21:1300-1301.
7.
BhattacharyyaNKepnesLJ. Associations between fatigue and medication use in chronic rhinosinusitis. Ear Nose Throat J. 2006;85:510, 512, 514-515.
8.
BowlesWHBokmeyerTJ. Staining of adult teeth by minocycline: binding of minocycline by specific proteins. J Esthet Dent. 1997;9:30-34.
9.
BursteinRHourvitzAEpsteinY. The relationship between short-term antibiotic treatments and fatigue in healthy individuals. Eur J Appl Physiol Occup Physiol. 1993;66:372-375.
10.
CarbonC. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47(suppl 3):9-14.
11.
ChassanyOMichauxABergmannJF. Drug-induced diarrhoea. Drug Saf. 2000;22:53-72.
12.
ChildsSG. Pathogenesis of tendon rupture secondary to fluoroquinolone therapy. Orthop Nurs. 2007;26:175-182.
13.
ConchieJMMunroeJDAndersonDO. The incidence of staining of permanent teeth by the tetracyclines. Can Med Assoc J. 1970;103:351-356.
14.
DavisRBrysonHM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutics efficacy. Drugs. 1994;47:677-700.
15.
EpsteinJH. Phototoxicity and photoallergy. Semin Cutan Med Surg. 1999;18:274-284.
16.
Food and Drug Administration. Drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. http://www.fda.gov/drugs/drugsafety/ucm341822.htm. Accessed July 1, 2013.
17.
FrostHM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3:211-237.
18.
GeriaANTajirianALKihiczakGSchwartzRA. Minocycline-induced skin pigmentation: an update. Acta Dermatovenerol Croat. 2009;17:123-126.
19.
GrossmanER. Tetracycline and staining of the teeth. JAMA. 1986;255:2442-2443.
20.
HallMMFinnoffJTSmithJ. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PMR2011;3:132-142.
21.
HicksonMD’SouzaALMuthuN. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ. 2007;335:80-83.
22.
Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm. Accessed March 5, 2013.
23.
JaimesEC. Lincocinamides and the incidence of antibiotic-associated colitis. Clin Ther. 1991;13:270-280.
24.
JohnstonBCSupinaALOspinaMVohraS. Probiotics in the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2007;2:CD004827.
25.
KannankerilPRodenDMDarbarD. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760-781.
26.
KotowskaMAlbrechtPSzajewskaH. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:583-590.
27.
LewisSJPottsLFBarryRE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-associated diarhoea in elderly patients. J Infect. 1998;36:171-174.
28.
LinderJAHuangESSteinmanMAGonzalesRStaffordS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259-268.
29.
LiuHH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33:353-369.
30.
MaronBJZipesDP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities—general considerations. J Am Coll Cardiol. 2005;45:1318-1321.
31.
McFarlandLV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16:292-307.
32.
McFarlandLV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe. 2009;15:274-280.
33.
McFarlandLV. Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822.
34.
McFarlandLV. Risk factors for antibiotic-associated diarrhea [in French]. Ann Med Interne (Paris). 1998;149:261-266.
35.
McGrewCA. Acute infections. In: McKeagDBMoellerJL, eds. ACSM’s Primary Care Sports Medicine. 2nd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2007:252.
36.
MenschikMNeumuüllerJSteinerCW. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro. Antimicrob Agents Chemother. 1997;41:2562-2565.
37.
MooreDE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25:345-372.
38.
NordCEHeimdahlAKagerL. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scan J Infect Dis. 1896;49(suppl):64-72.
RayWAMurrayKTHallKArbogastPGSteinCM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-1890.
41.
ReedDNGreggFOCorpeRS. Minocycline-induced black bone disease encountered during total knee arthroplasty. Orthopedics. 2012;35:e737-e739.
42.
RubinsteinECammJ. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49:593-596.
43.
SanchezARogersRS3rdSheridanPJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43:709-715.
44.
SanguinettiMCJiangCCurranMEKeatingMT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
45.
SansoneJWilsmanNJLeifermanEMConwayJHutsonPNoonanKJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009;29:189-195.
46.
SeegerJDWestWAFifeDNoelGJJohnsonLNWalkerAM. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15:784-792.
47.
ShantsilaEWatsonTLipGY. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace. 2007;9(suppl 4):iv37-iv44.
48.
SmithKLeydenJJ. Safety of doxycycline and minocycline: a systemic review. Clin Ther. 2005;27:1329-1342.
49.
SodeJObelNHallasJLassenA. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Parmacol. 2007;63:499-503.
50.
StahlmannR. Safety profile of the quinolones. J Antimicrob Chemother. 1990;26(suppl D):31-44.
51.
SurawiczCM. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?Chemotherapy. 2005;51(suppl 1):81-89.
52.
SvenssonCKCowenEWGaspariAA. Cutaneous drug reactions. Pharmacol Rev. 2001;53:357-379.
53.
TsikourisJPPeetersMJCoxCDMeyerroseGESeifertCF. Effects of three flouroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol. 2006;11:52-56.
54.
TurckDBernetJPMarxJ. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37:22-26.
55.
van der LindenPDSturkenboomMCHeringsRMLeufkensHMRowlandsSStrickerBH. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163:1801-1807.
56.
van der LindenPDSturkenboomMCHeringsRMLeufkensHGStrickerBH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324:1306-1307.
57.
van der LindenPDvan PuijenbrockEPFeenstraJ. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum. 2001;45:235-239.
WainwrightNJCollinsPFergusonJ. Photosensitivity associated with antibacterial agents. Drug Saf. 1993;9:437-440.
60.
WeberFHJrRichardsRDMcCallumRW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993;88:485-490.
61.
WiseBLPeloquinCChoiHLaneNEZhangY. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012;125:1228.e23-1228.e28.
62.
YapYGCammAJ. Drug induced QT prolongation and torsades de pointes. BMJ. 2003;89:1363-1372.
63.
YapLMFoleyPACrouchRBBakerCS. Drug-induced solar urticaria due to tetracycline. Australas J Dermatol. 2000;41:181-184.
64.
YongCKPrendivilleJPeacockDWongLTDavidsonAG. An unusual presentation of doxycycline-induced photosensitivity. Pediatrics. 2000;106:E13.
65.
ZambonAPoloFriz HContieroPCorraoG. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf. 2009;32:159-167.
66.
ZipesDPCammAJBorggrefeM. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006;27:2099-2140.
